About the 47th Symposium on Hormones and Cell Regulation
About the 47th Symposium on Hormones and Cell Regulation
G protein-coupled receptors (GPCRs) are encoded by the most important gene family in the human genome, representing 3% of the protein coding genes (820 genes).
These cell surface receptors are expressed in every cell, and each cell type express a large set of these receptors, varying during development and physiological situations. Accordingly, GPCRs represent about 30% of the targets of therapeutic drugs actually on the market, and still represent a major interest in drug development programs.
Whereas GPCRs were well recognized as targets for the treatment for various diseases including allergy, psychiatric and neurologic, cardiovascular among others, recent development revealed their high potential for the treatment of various important diseases like cancers, brain and metabolic diseases, diabetes.
The Mont Ste Odile meetings were established in the 50's by Jacques Dumont with the idea to bring together scientists from both sides of the last world war to strongly favor reconciliation. This meeting concentrates on the mode of action of hormones and other messengers in cell regulation, providing key information for drug development.
The 47th meeting will be on Oct 1st-Oct 4th 2025, and dedicated to GPCRs as novel targets for diseases.
The meeting will bring three keynote speakers, leaders in the field of GPCRs for the analysis of their structure, and their interest in cancer and brain disease treatments.
It will be organized around 5 mini-symposia of 3-4 invited speakers and will cover novel topics in the field:
1) The analysis of GPCRs at the single molecule level, elucidating their very precise location, and their structural dynamics, as important aspects of their function and for the understanding of drug action;
2) The recent observations that GPCRs offer novel possibilities to treat cancers;
3) How GPCRs involved in the control of metabolism can be used to treat various diseases;
4) Novel strategies to treat brain diseases, including immunotherapies targeting GPCRs
5) The use of AI to better characterize GPCR signaling properties and accelerate drug discovery.
Support will be provided to help young scientists to participate, and a
poster session will be organized to allow them to present their work.
In each session, three-four young scientists will be selected for a short presentation based on the abstracts submitted.
